The Food and Drug Administration issued a Complete Response Letter to Lipocine Inc. (Nasdaq: LPCN) for LPCN 1021. Shares of the specially pharmaceutical plummeted $3.17 to close at $3.10.
Lipocine receives CRL
June 29, 2016 at 16:54 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|